In the latter case, a chemotherapeutic approach based on several drugs, such as Dacarbazine (an alkylating agent), Vemurafenib (BRAF kinase inhibitor), Ipilimumab (monoclonal antibody targeting for cytotoxic T-lymphocyte antigen-4), Pemrolizumab (monoclonal IgG4 antibody), and Nivolumab (monoclonal antibody targeting for Programmed Death-1 protein) [72], is the most efficient strategy to treat melanoma. This evidence concerns the gene BRAF and melanoma.